Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.19.2
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
May 10, 2018
Jan. 31, 2018
Jan. 13, 2017
Sep. 07, 2016
Oct. 22, 2013
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Feb. 28, 2018
Warrants to purchase ordinary shares 29,763                      
Exercise price $ 4.80                     $ 4.25
Research and development $ 55,900         $ 1,637,387 $ 1,438,704 $ 3,929,558   $ 4,636,287 $ 4,438,264  
Warrants expiration term Jan. 31, 2024                      
Volatility rate           84.50%         75.00%  
Dividend rate           0.00%   0.00%     0.00%  
Reversed prior period expenses of intangible assets               $ 200,000        
Rent expense           $ 25,059   $ 115,276 $ 73,013      
June 31, 2019 [Member]                        
Options to purchase common stock               100,000        
eNOGenorator [Member] | After Six Months [Member]                        
Future payments based on certain milestones   $ 1,500,000                    
NitricGen, Inc [Member                        
Future payments based on certain milestones   2,000,000                    
Fair value of options   295,000                    
Milestone payments and fair value of options   495,000                    
Reversed prior period expenses of intangible assets   200,000                    
Circassia Pharmaceuticals PLC [Member]                        
Future payments based on certain milestones               $ 250,000        
Patent License Agreement [Member]                        
Non-refundable upfront fee paid         $ 150,000              
Royalty percentage owed on sale of licensed product revenues         5.00%              
Minimum amount of royalties owed per annum         $ 50,000              
Option Agreement [Member]                        
Acquisition cost to purchase intellectual property assets and rights       $ 25,000                
Payments for development and milestone payment     $ 500,000                  
Milestone payments     87,000,000                  
Sales related milestones payments     $ 83,000,000                  
Warrants to purchase ordinary shares     178,570                  
Exercise price     $ 4.80                  
Shares exchange, description     The shares exchange was at 1:1 ratio                  
Research and development     $ 479,700                  
Execution Agreement [Member]                        
Future payments based on certain milestones   $ 180,000                    
Execution Agreement [Member] | NitricGen, Inc [Member                        
Exercise price   $ 6.90                    
Future payments based on certain milestones   $ 100,000                    
Payment to related parties   $ 100,000                    
Options to purchase common stock   100,000                    
Volatility rate   79.90%                    
Risk-free interest rate   2.50%                    
Option expiration term   5 years                    
Dividend rate   0.00%                    
Lease Agreement [Member]                        
Lease agreement expiration, description               Expire on April 2021 and June 2023